Europe unveils science strategy as it looks to become an ‘AI continent’
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
List view / Grid view
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
Offers potential symptomatic relief for cancer patients with chemotherapy-induced peripheral neuropathy (CIPN).
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.